These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18210765)

  • 1. Metabolic effects of rosiglitazone and metformin in Greek patients with recently diagnosed type 2 diabetes.
    Iliadis F; Kadoglou NP; Hatzitolios A; Karamouzis M; Alevizos M; Karamitsos D
    In Vivo; 2007; 21(6):1107-14. PubMed ID: 18210765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
    Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
    Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio.
    Mulligan K; Yang Y; Wininger DA; Koletar SL; Parker RA; Alston-Smith BL; Schouten JT; Fielding RA; Basar MT; Grinspoon S
    AIDS; 2007 Jan; 21(1):47-57. PubMed ID: 17148967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
    Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.
    Brunani A; Caumo A; Graci S; Castagna G; Viberti G; Liuzzi A
    Diabetes Obes Metab; 2008 Jun; 10(6):460-7. PubMed ID: 17394563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
    Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
    Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Piccinni MN; Fogari E; Salvadeo S; Ciccarelli L; Fogari R
    Diabetes Res Clin Pract; 2005 Jul; 69(1):5-13. PubMed ID: 15955382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    Intern Med J; 2007 Feb; 37(2):79-86. PubMed ID: 17229249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
    Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M
    Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes.
    Bermúdez V; Cano R; Cano C; Bermúdez F; Leal E; Acosta K; Mengual E; Arraiz N; Briceño C; Gómez J; Bustamante M; Aparicio D; Cabrera M; Valdelamar L; Rodriguez M; Manuel V; Hernández R
    Am J Ther; 2008; 15(4):409-16. PubMed ID: 18645347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes.
    Stewart MW; Cirkel DT; Furuseth K; Donaldson J; Biswas N; Starkie MG; Phenekos C; Hamann A
    Diabet Med; 2006 Oct; 23(10):1069-78. PubMed ID: 16978370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
    Stocker DJ; Taylor AJ; Langley RW; Jezior MR; Vigersky RA
    Am Heart J; 2007 Mar; 153(3):445.e1-6. PubMed ID: 17307426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
    Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre study.
    Gao H; Xiao W; Wang C; Zhang J; Yang Y; Yang J; Yang W; Hong T
    Int J Clin Pract; 2008 May; 62(5):695-700. PubMed ID: 18412932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus.
    Kadoglou NP; Iliadis F; Angelopoulou N; Perrea D; Liapis CD; Alevizos M
    Diabet Med; 2008 Mar; 25(3):333-40. PubMed ID: 18307460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastroprotective effects of the insulin sensitizers rosiglitazone and metformin against indomethacin-induced gastric ulcers in Type 2 diabetic rats.
    Morsy MA; Ashour OM; Fouad AA; Abdel-Gaber SA
    Clin Exp Pharmacol Physiol; 2010 Feb; 37(2):173-7. PubMed ID: 19566821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects.
    James AP; Watts GF; Mamo JC
    Diabetes Obes Metab; 2005 Jul; 7(4):381-9. PubMed ID: 15955124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.